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ABSTRACT
Elevated expression of Wnt5a is associated with malignancy, cell invasion, 
and metastasis. The role of Wnt5a expression in breast cancer remains elusive. We 
investigated the significance of Wnt5a expression in breast cancer. The relationship 
between Wnt5a expression and clinicopathologic factors was assessed in invasive 
breast cancer (n = 178) resected at Hiroshima University Hospital between January 
2011 and February 2014. Wnt5a was expressed in 69 of 178 cases (39%) of invasive 
breast cancer and correlated strongly with estrogen receptor (ER) expression 
(P < 0.001). Wnt5a expression in ER-positive breast cancer correlated significantly 
with lymph node metastasis, nuclear grade, and lymphatic invasion. The recurrence-
free survival was shorter in breast cancer patients with Wnt5a expression than in 
those without (P = 0.024). The migratory capacity of ER-positive breast cancer 
cells increased with constitutive expression of Wnt5a and decreased with Wnt5a 
knockdown. DNA microarray analysis identified activated leukocyte cell adhesion 
molecule (ALCAM) as the primary gene induced by Wnt5a. ALCAM was expressed 
in 69% of Wnt5a-positive but only 27% of Wnt5a-negative cancers (κ = 0.444; 
P < 0.001). The inhibition of ALCAM reversed the enhanced migratory effect of Wnt5a, 
confirming the importance of this protein in the migration of ER-positive breast cancer 
cells. Wnt5a expression is related to high malignancy and a poor prognosis in ER-
positive breast cancer. We suspect that Wnt5a expression increases the malignancy 
of breast cancer by increasing the migratory capacity of cancer cells through the 
induction of ALCAM expression.
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INTRODUCTION
Wnt signaling occurs in β-catenin-dependent 
pathways, through β-catenin regulates the expression 
of many genes, and in the β-catenin-independent planar 
cell polarity and Wnt/Ca2+ pathways [1, 2]. β-catenin-
dependent pathways are involved in some cancers, for 
example, familial polyposis, in which the adenomatous 
polyposis coli mutation causes the accumulation of 
β-catenin in the nucleus, resulting in colorectal cancer 
[2, 3]. In β-catenin-independent pathways, Wnt5a is a 
representative activating ligand involved in cell motility 
and cell polarity through downstream signaling (e.g., 
JNK phosphorylation) [4]. Wnt5a expression correlates 
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significantly with malignancy and stage of progression in 
malignant melanoma [5, 6], gastric cancer [7–9], prostate 
cancer [10], lung cancer [11], and pancreatic cancer [12]. 
In contrast, Wnt5a is a tumor suppressor in colorectal 
cancer [13], thyroid cancer [14], liver cancer [15], and 
malignant lymphoma [16]. Thus, the effect of Wnt5a 
expression differs between organs.
Whether Wnt5a expression in breast cancer correlates 
with pathological factors such as lymph node metastasis 
and grade is unknown. While a significant correlation 
between the immunohistochemical disappearance of Wnt5a 
expression and poor prognosis [17, 18] has been reported, 
these studies do not distinguish between breast cancers 
subtypes. Breast cancer is classified into four subtypes 
based on the expression of the estrogen receptor (ER) and 
human epidermal growth factor receptor 2 (HER2) [19, 20]. 
Because ER-positive and -negative breast cancers derive 
from different tissues (ductal epithelium and basal cells, 
respectively), the two subtypes are biologically distinct. 
ER-positive breast cancers progress slowly, whereas those 
that are ER-negative are highly malignant and have a poor 
prognosis. In previous studies, the inclusion of all subtypes, 
with their remarkably distinct prognoses, likely interfered 
with the accurate determination of the role of Wnt5a in 
breast cancer.
A positive correlation is reported between Wnt5a 
expression level and ER-positive breast cancer, as 
determined using breast cancer specimens [17, 18]. A 
correlation was observed between the PIK3CA mutation 
and Wnt5a expression based on the examination of 43 
cases of ER-positive tumors [21]. Another study reports no 
significant correlation between the expression of Wnt5a 
and ER status, as determined by examination of 94 stained 
breast cancer specimens [22]. We believe that to determine 
the role of Wnt5a expression in breast cancer, the level of 
Wnt5a expression in each of the breast cancer subtypes 
must first be determined.
The mechanism of malignant transformation by 
Wnt5a has been studied in a variety of cancers. Cell 
motility in Wnt5a-positive gastric cancer is increased 
through activation of FAK and Rac to induce malignant 
transformation [7, 8]. One study of breast cancer 
reports an increase in expression of Wnt5a/b and their 
respective receptors Ror1 and 2 in brain metastases [23]. 
Other studies report that Wnt5a expression increases 
the malignancy of breast cancer through activation of 
tumor-related macrophages [24] or the promotion of cell 
migration [25]. However, to date, no study has described 
the mechanism underlying malignant transformation by 
Wnt5a in breast cancer.
In this study, we examine the significance of 
Wnt5a expression in breast cancer by determining the 
clinicopathologic characteristics of Wnt5a-positive breast 
cancers using Wnt5a immunohistochemical analysis of 
breast cancer specimens. We investigate the mechanism 
of malignant transformation in breast cancer by Wnt5a 
through biological analyses of cultured cell s.
RESULTS
Wnt5a is expressed in ER-positive breast cancer
We observed weak Wnt5a expression in non-tumor 
ductal epithelial cells but none in basal or stromal cells 
(Figure 1Aa, 1Ab). Wnt5a was expressed in the cytoplasm 
but not the nucleus of breast cancer cells (Figure 1Aa, 
1Ac). Wnt5a expression scores are shown in Figure 1B. 
Scores of 0, 1+, 2+, and 3+ accounted for 20%, 25%, 16%, 
and 39% of the specimen scores, respectively. A score of 
3+ was defined to be positive for Wnt5a expression.
Of the 178 cases of invasive breast cancer, 69 
(39%) were Wnt5a-positive and 109 (61%) were Wnt5a-
negative (Table 1, Supplementary Table 1). A very strong 
correlation was observed between Wnt5a expression 
and positivity for ER or PgR. Wnt5a expression was 
extremely low in ER-negative breast cancers. There was 
no correlation between Wnt5a expression and HER2 
positivity. Wnt5a-positive breast cancers were classified 
into subtypes based on ER status, as shown in Table 1.
Wnt5a expression is associated with high-grade 
malignancy in ER-positive breast cancer
Because we observed that Wnt5a expression is 
associated with ER-positive breast cancer, we investigated 
the pathological factors and prognosis of ER-positive 
breast cancers exclusively. Analysis of 153  ER-positive 
cases revealed a significant difference between Wnt5a-
positive and negative breast cancer in the presence of 
lymph node metastasis (P < 0.001), nuclear grade (P = 
0.004), and lymphatic invasion (P = 0.002) (Table 2). 
Although no significant correlation was seen, there 
were clear trends toward a relationship between Wnt5a 
expression and the presence of vessel invasion (P = 
0.050), tumor size (P = 0.069), and Ki-67 labeling index 
(P = 0.058). These data suggest that malignancy is higher 
in Wnt5a-positive breast cancer that is also ER-positive 
rather than ER-negative. Comparison of recurrence-free 
survival, for which 5-year survival rates were 81.1% 
and 100% in Wnt5a-positive and Wnt5a-negative breast 
cancers, respectively, revealed a significant difference 
according to statistical analysis using the log-rank test (P
= 0.024) (Figure 2). The clinicopathological factors and 
recurrence sites of ER-positive breast cancer are sho wn in 
Supplementary Table 2.
Migratory capacity of Wnt5a-expressing breast 
cancer cells
We prepared MCF-7, an ER-positive breast cancer 
cell line expressing no Wnt5a, and forced it to express 
Wnt5a constitutively (MCF-7/Wnt5a cells). These cells 
showed no change in the levels of proteins involved  in 
breast cancer–related signaling pathways or β-catenin-
dependent pathways, such as ER, β-catenin, and cyclin 
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D1 (Figure 3A). There was no significant difference in 
the proliferative capacity between MCF-7/Wnt5a and 
control MCF-7 cells (Figure 3B). As Wnt5a is reported to 
associate with cell migration, we conducted cell migration 
assays to determine the migratory capacity of Wnt5a-
positive breast cancer cells. We also tested Wnt5a-silenced 
MCF-7/Wnt5a cells (MCF-7/Wnt5a + Wnt5a-siRNA 
cells), bringing the total number of cell types investigated 
to three. The migratory capacity of MCF-7/Wnt5a cells 
increased significantly 12 h later, whereas knockdown of 
Figure 1: Wnt5a expression in breast cancer using breast cancer specimens. (A) Immunohistochemical staining for Wnt5a in 
invasive breast cancer. (a) Wnt5a expression in invasive breast cancer. (b) Wnt5a expressed weakly in cytoplasm in non-tumor mammary 
duct. (c) Wnt5a expressed strongly in invasive breast cance r a: bar, 500 µm, magniﬁ cation ×40; b, c: bar 50 µm, ×400 (B) Evaluation of 
Wnt5a expression was scored as 0, 1+, 2+, or 3+, taking into consideration both staining proportion and intensity. Scores 0–2+, negative; 
Score 3+, positive. bar, 50 µm, ×400.
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Wnt5a resulted in a lower increase in migratory capacity 
(Fig ure 3C, 3D).
We investigated the endogenous Wnt5a expression 
in several ER-positive breast cancer cell lines. A strong 
endogenous Wnt5a expression was observed in MDA-
MB-175-VII cells (Figure 4A, Supplementary Figure 1). 
The knockdown of Wnt5a in MDA-MB-175-VII cells 
significantly decreased migratory capacity, whereas 
knockdown of Wnt5a in MDA-MB-361 cells did not 
decrease migratory capacity (Figure 4B).
DNA microarray analysis using MCF-7/Wnt5a 
cells
To investigate the mechanism by which Wnt5a 
expression leads to increased migratory activity, we 
conducted DNA microarray analysis of MCF-7/Wnt5a 
cells and control cells. We identif ied several genes 
upregulated (Table 3) and several downregul ated 
(Supplementary Table 3) by Wnt5a. One of  the upregulated 
genes, ALCAM, is a member of the immunoglobulin 
superfamily that is localized in the plasma membrane. 
ALCAM is involved in apoptosis, angiogenesis, migration, 
and invas ion [26–28]. We focused on ALCAM and 
investigated its protein expression by Western blotting, 
observing a marked increase of ALCAM in MCF-7/
Wnt5a cells and decrease of ALCAM in MCF-7/Wnt5a 
and MDA-MB-175-VII cells by the knockdown of Wnt5a 
(Supplementary Figure 2, Figure 5A).
ALCAM expression correlates with Wnt5a 
expression in ER-positive breast cancer
We examined the expression of Wnt5a and ALCAM 
in breast cancer specimens. Scoring ALCAM expression 
as 0–3, we observed that 46% had a score of 3+, which 
was defined to be positive (Figure 5 B). In 153 cases of 
ER-positive breast cancer, ALCAM was expressed in 
69% of Wnt5a-positive breast cancers but only 27% of 
Wnt5a-negative breast cancers, a statistically significant 
correlation between Wnt5a and A LCAM expression (Table 
4) (κ = 0.444; P < 0.001). Serial sections of pathological 
specimens of invasive breast cancer reve aled that Wnt5a 
was expressed in the cytoplasm, whereas ALCAM was 
expressed in  the pla sma membrane (Figure 5C).
Knockdown of ALCAM also reduces migratory 
capacity
Our data indicate that the knockdown of Wnt5a 
reduced ALCAM expression and migratory capacity 
(Figures 3C, 3D and 4B). We next conducted cell 
migration assays to determine whether inhibition of 
ALCAM decreases migratory capacity as with the 
knockdown of Wnt5a. The migratory capacity of MDA-
MB-175-VII cells significantly decreased 12 h af ter t he 
knockdown of ALCAM (Figure 6A, 6B), suggesting 
that cell migration is regulated via the Wnt5a-ALCAM 
signaling pathway in ER-positive breast cancer.
DISCUSSION
We examined nearly 200 specimens using 
an antibody already confirmed accurate in 
immunohistochemical analysis of Wnt5a-positive gastric 
cancers [7]. We observed a high correlation between 
Wnt5a and ER expression in breast cancers. In addition, 
our results indicate that Wnt5a-positivity strongly 
correlated with the presence of lymph node metastasis, 
lymphatic invasion, vessel invasion, and nuclear grade in 
ER-positive breast cancer. We also observed that among 
ER-positive breast cancers, those expressing Wnt5a were 
more malignant and had a poorer prognosis than those that 
did not express Wnt5a.
We also investigated the mechanism underlying 
malignant transformation by Wnt5a. Previous studies 
Table 1: Relation of Wnt5a expression with ER, PgR and HER-2 in breast cancer
Wnt5a expression
Total (n = 178)   Negative (n = 109) Positive (n = 69) P value  
ER, N (%) 
   Negative      25 (14) 24 (22)  1 (1)
   Positive     153 (86) 85 (78) 68 (99)  <0.001
PgR, N (%) 
   Negative      38 (21) 34 (31)  4 (6)
   Positive     140 (79) 75 (69) 65 (94)  <0.001
HER2, N (%) 
   Negative     159 (89) 96 (88) 63 (91)
   Positive      19 (11) 13 (12)  6 (9)   0.496   
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have reported that Wnt5a is involved in increased cell 
proliferation, differentiation, migration, adhesion, 
and changes in cell polarity [4]. We observed that the 
migratory capacity of ER-positive breast cancer cells 
forced to express Wnt5a increased and the knockdown of 
Wnt5a led to a decrease in migratory capacity, whereas 
cell proliferation remained unchanged. DNA microarray 
analysis revealed that ALCAM expression in Wnt5a-
positive breast cancer cells is induced by Wnt5a. ALCAM 
expression in breast cancer is reported to correlate with ER 
expression, lymph node metastasis, distant metastasis, and 
a poor progn os is [26, 30, 31]. Activation of the β-catenin-
independent pathway induces ALCAM expression, and 
JNK located downstream of Wnt5a induces ALCAM 
expr ession [32]. We explored the function of Wnt5a 
and ALCAM on cell migration in ER-positive breast 
cancer and found that the knockdown of Wnt5a reduced 
ALCAM expression and cell migration. Furthermore, the 
knockdown of ALCAM also showed the reduction of cell 
migration, suggesting that cell migration is regulated via 
the Wnt5a-ALCAM signaling pathway in ER-positive 
breast cancer. Our investigation of breast cancer tissues 
also revealed that Wnt5a expression correlates with 
ALCAM expression in ER-positive breast cancers, 
indicating that Wnt5a-positive/ALCAM-positive breast 
cancers form a biologically distinct subgroup of ER-
positive breast cancers.
Wnt5a expression has been shown to correlate with 
tumor progression in a variety of cancers. However, the 
function of Wnt5a has been reported as both a tumor 
Table 2: Relation between Wnt5a expression and clinicopathological factors in ER-positive breast cancer
Wnt5a expression
Total (N = 153)  Negative (n = 85) Positive (n = 68) P value
Age (median, range)  63, 35–86 57.5, 34–87 0.065
Age, N (%)
≤45 28 (18) 13 (15) 15 (22)
>45 125 (82) 72 (85) 53 (78) 0.282
Menopausal status, N (%) 
Premenopausal 58 (38) 27 (32) 31 (46)
Postmenopausal 95 (62) 58 (68) 37 (54) 0.080
Tumor size, N (%)
pT1 ≤ 20 mm 104 (44) 63 (74) 41 (60)
pT2/pT3 > 20 mm 49 (56) 22 (26) 27 (40) 0.069
Lymph node metastasis, N (%)
Negative 103 (67) 72 (85) 31 (46)
Positive 50 (33) 13 (15) 37 (54) <0.001
Nuclear grade, N (%)
1/2  85 (56) 56 (66) 29 (43)
3  68 (44) 29 (34) 39 (57)  0.004
Lymphatic invasion, N (%)
Negative 101 (66) 65 (76) 36 (53)
Positive 52 (34) 20 (24) 32 (47) 0.002
Vessel invasion, N (%)
Negative 142 (93) 82 (96) 60 (88)
Positive 11 (7)  3 (4)  8 (12) 0.050
Ki-67, N (%)
0–20  67 (79) 43 (51)        24 (35)
21–100 86 (56) 42 (49) 44 (65) 0.058
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suppressor and a tumor promotor in breast cancer. The 
loss of Wnt5a was found to be an indicator of poor 
prognosis in a study of whole breast cancers, including 
different subtypes [17]. However, accurate assessment 
of Wnt5a function in different subtypes is difficult 
because mutations in the signaling molecules differ 
between different subtypes. Therefore, it is important to 
determine which subtypes express Wnt5a. The majority 
of the previous reports on Wnt5a-positive breast cancer 
classified these cancers based solely on the presence or 
absence of Wnt5a expression, without regard to subtype. 
In addition, the number of cases studied in these reports 
was small, and there was not a suitable antibody available 
for immunohistochemical analysis of tissues.
Wnt5a overexpression was observed in ER-positive 
breast cancers with a mutation in PIK3CA [19]; PIK3CA 
mutations are seen in approximately 30% of ER-positive 
breast cancers and cause resistance to th er apy [33, 34]. 
Together with these reports, our results suggest that Wnt5a 
is involved in the malignant transformation and/or relapse 
of ER-positive breast cancer. Wnt5a-Ror2 signals increase 
the expression of receptor activator of nuclear factor-
κB (RANK) in osteoclast precursors by activating JNK 
and recruiting c-Jun, thereby enhancing RANK ligand 
(RANKL)-induced osteoclastoge nesis [35]. Interestingly, 
all patients with recurrent breast cancer in this study had 
bone metastasis, suggesting that Wnt5a plays a role in 
bone metastasis in breast cancer.
Increased Wnt5a expression has been observed in 
ER-positive breast cancers with PIK3CA mutations [19]. 
Thus, we propose that mutations in PIK3CA induce Wnt5a 
expression, which activates JNK to induce ALCAM 
expression, causing malignant transformation of ER-
positive breast cancer cells. It is unknown whether Wnt5a 
Figure 2: Relationship between recurrence-free survival and Wnt 5a in 153 ER-positive breast cancer patients. The 
recurrence-free survival rates were analyzed according to Wnt5a immunohistochemistry. The mean 5-year recurrence-free survival rates 
were 100% for Wnt5a negative breast cancer and 81.1% for Wnt5a negative breast cancer. Wnt5a expression was signiﬁ cantly associated 
with poor recurrence-free survival in ER-positive cancer patients (P = 0.024).
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Figure 3: Migratory capacity of Wnt5a-expressing breast cancer cells. (A) The expression levels of β-catenin, ER, and cyclin 
D in MCF-7/Wnt5a and control MCF-7 cells. (B) The proliferative capacity in MCF-7/Wnt5a and control MCF-7 cells. Data are presented 
as the mean ± SE of three proliferation assays. (C, D) The migratory capacity of MCF-7, MCF-7/Wnt5a + sc, and MCF-7/Wnt5a + Wnt5a-
siRNA cells. Data are presented as the mean ± SE of three migration assays. Data were evaluated using the Mann–Whitney U-test.
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expression is induced by activation of PI3K/AKT/mTOR 
signaling caused by PIK3CA mutation in ER-positive 
breast cancers. This question will be the focus of our 
future studies.
In conclusion, Wnt5a induces malignant 
transformation in ER-positive breast cancers. Increased 
invasiveness resulting from upregulated ALCAM 
expression suggested the mechanism whereby Wnt5a 
induces malignant transformation. Wnt5a may be useful 
as a predictor of malignancy, a therapeutic target, and a 
prognostic indicator in ER-positive breast cancer.
MATERIALS AND METHODS
Sample selection
Patients with invasive breast cancer treated 
surgically between January 2011 and February 2014 at 
Figure 4: Knockdown of Wnt5a decreases the migratory capacity of MDA-MB-175-VII cells. (A) The Wnt5a expression 
of MDA-MB-175-VII and MDA-MB-361 cells transfected with Wnt5a-siRNAs (Wnt5a-siRNA #1 and #2) and sc. (B) The migratory 
capacity of MDA-MB-175-VII and MDA-MB-361 cells transfected with Wnt5a-siRNAs and sc. Data are presented as the mean ± SE of 
three migration assays. Data were evaluated using the Mann–Whitney U-test.
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Hiroshima University Hospital in Japan were sequentially 
enrolled in this study. Patients treated with neoadjuvant 
chemotherapy were excluded. This study was approved 
by the institutional review board of Hiroshima University 
Hospital (No. 926), and all participants provided written 
informed consent for the use of their tissue specimens. 
Each participant’s medical information was obtained from 
medical records.
Immunohistochemistry
Immunohistochemistry was performed as 
previously described [22]. Antigen retrieval was made 
using proteinase treatment (Proteinase K S3004; Dako, 
Carpinteria, California, USA) for 2 min and 30 s in room 
air. The sections were reacted with the polyclonal anti-
Wnt5a antibody, a kind gift from Prof. Akira Kikuchi 
(Department of Molecular Biology and Medicine, Osaka 
University, Suita, Japan) at 4° C overnight. Activated 
leukocyte cell adhesion molecule (ALCAM) was stained 
with anti-ALCAM antibody (clone MOG/07; Leica 
Biosystems, Wetzlar, Hesse, Germany). Antigen retrieval 
was made using heat-treatment for 20 min at 98° C in 
citrate buffer (pH 6.0). Wnt5a and ALCAM expression 
were scored as 0, 1+, 2+, or 3+, taking into consideration 
staining proportion and intensity. The Wnt5a and ALCAM 
scores were assessed as follows: 0, no staining or staining 
in ≤10% of invasive tumor cells; 1+, weak staining in 
>10% of invasive tumor cells; 2+, moderate staining in 
>10% of invasive tumor cells or strong staining in >10% 
and ≤30% of invasive tumor cells; 3+, strong staining in 
>30% of invasive tumor cells. A score of 3+ was defined 
as positive for both Wnt5a and ALCAM. The scoring was 
independently conducted by two investigators who had 
no knowledge of the patients’ clinical data. An automatic 
staining machine was used for immunohistochemical 
staining of the following biomarkers: ER, PgR (SP-1, 
monoclonal antibody; Ventana Medical Systems, Tucson, 
Arizona, USA), HER2 (polyclonal antibody; Dako), and 
Ki-67 (30-9, monoclonal antibody; Ventana Medical 
Systems). A proportion of nuclear staining of ER and PgR 
≥1% was considered positive expression. HER2 expression 
was evaluated accordingly as previously described [26].
Cell culture and transfection
MCF-7 cells were obtained from American Type 
Culture Collection (Manassas, Virginia, USA) and 
were grown in RPMI-1640 medium supplemented with 
10% fetal bovine serum. MCF-7 cells were transiently 
transfected with pPGK-neo/Wnt5a using Lipofectamine 
LTX with PLUS reagent (Life Technologies, Carlsbad, 
California, USA). pPGK-neo/Wnt5a was a kind gift from 
Prof. Akira Kikuchi. MCF-7 cells stably expressing mouse 
Wnt5a (MCF-7/Wnt5a) were generated by selection with 
200 μg/mL G418.
Table 3: Genes up-regulated by expression of Wnt5a
Fold changes 
(ratio MCF7 Wnt5a/MCF7 control)
No. Gene symbol Gene name MCF7 Wnt5a ①
MCF7 
Wnt5a ②
MCF7 
Wnt5a ③
 1 ID1 Inhibitor of DNA binding 1  3.94 2.08 2.28
 2 MAOA Amine oxidase A 2.85 2.26 4.85
 3 ALCAM Activated leukocyte cell adhesion molecule 3.25 2.81 3.07
 4 AKR1C3 Aldo-keto reductase family 1 member C3 3.18 2.18 5.17
 5 MARCKS    Myristoylated alanine-rich C-kinase substrate 5.93 2.23 10.37
 6 CALML5 Calmodulin-like protein 5  2.87 2.53 4.10
 7 NOL11 Nucleolar protein 11 2.85 2.67 2.63
 8 STX12 Syntaxin-12  3.70 3.84 5.08
 9 CCDC104 Coiled-coil domain-containing protein 104 2.91   2.79 3.91
10 ITM2B Integral membrane protein 2B 3.13 3.04 3.18
11 CHMP4A Charged multivesicular body protein 4a 3.63 2.96 3.03
12 D2HGDH D-2-hydroxyglutarate dehydrogenase 3.23 3.20 3.76
13 CRK   Adapter molecule crk 3.00  3.15 3.00
14 DIABLO Direct IAP binding protein with low pI 3.84 3.15 4.04
15 ZNF446 Zinc ﬁ nger protein 446  2.03 2.05 2.15
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We sough breast cancer cells expressing ER, Wnt5a, 
and ALCAM endogenously to address the mechanism by 
which ALCAM mediates the ability of Wnt5a to promote 
migration of ER-positive breast cancer cells. MDA-
MB-175-VII, MDA-MB-361, ZR-75-30, ZR-75-1, and 
CAMA-1 cells were obtained from American Type Culture 
Collection. MDA-MB-175-VII, MDA-MB-361, and 
CAMA-1 cells were grown in Leibovitz’s L-15 medium 
supplemented with 10% fetal bovine serum, Leibovitz’s 
L-15 medium supplemented with 20% fetal bovine serum, 
and Eagle’s minimum essential medium supplemented 
with 10% fetal bovine serum, respectively. ZR-75-30 
and ZR-75-1 cells were grown in RPMI-1640 medium 
supplemented with 10% fetal bovine serum.
siRNA
In analyses with small interfering RNAs 
(siRNAs) for Wnt5a, the human Wnt-5a mRNA target 
sequences, 5ʹ-TATCAATTCCGACATCGAATT-3ʹ and 
5ʹ-UAUCAAUUCCGACAUCGAATT-3ʹ were used (Life 
Technologies). For ALCAM, the human ALCAM mRNA 
Figure 5: Co-expression of Wnt5a and ALCAM in ER-positive breast cancer tissue. (A) ALCAM expression was reduc ed 
by knockdown of Wnt5a. (B) Evaluation of ALCAM expression was scored  as 0, 1 +, 2+, or 3+. Scoring of ALCAM was performed with 
the same evaluation  as Wn t5a. (C) Co-expression of Wnt5a and ALCAM in breast cancer tissue.
Table 4: Relationship between Wnt5a expression and ALCAM expression in ER-positive breast cancer
ALCAM
   Total (N = 153) Negative (N = 83)   Positive (N = 70) P value
Wnt5a
Negative (N = 85) 62 (73%) 23 (27%)
Positive (N = 68) 21 (31%) 47 (69%) <0.001
kappa coefﬁ cient κ = 0.444. 95% CI.: [0.3013, 0.5869].
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target sequences, 5ʹ-GCAUAUGGAGAUACCAUUATT-
3ʹ and 5ʹ-GGACCUCGGUAAUAUGGAATT-3ʹ were 
used (Life Technologies). To transfect siRNA into MCF-
7 cells expressing Wnt5a, trypsinized MCF-7 cells were 
suspended in Opti-MEM (Life Technologies) at 106 cells 
per 100 µL, siRNA was added (90 pmol), and cells were 
mixed with RNAi max (Life Technologies) in Opti-MEM.
Cell migration assay
To assess cell migration activity, a two-chamber 
transmigration assay was performed as previously 
described [36, 37]. MCF-7/Wnt5a cells (5.0 × 104 cells), 
5.0 × 104 MCF-7/Wnt5a cells + scramble (sc), 5.0 × 104 
MCF-7/Wnt5a + Wnt5a-siRNA, 5.0 × 104 MCF-7/Wnt5a 
+ ALCAM-siRNA, and 5.0 × 104 MCF-7 cells with 500 μL 
RPMI-1640 medium were seeded into the upper chamber, 
and 750 μL NIH3T3-conditioned medium and 750 μL 
RPMI-1640 medium (10% FBS) was added to the lower 
chamber of a 12-well Multi Well Plate (BD Biosciences, 
San Jose, California, USA). Cells were incubated for 12 h 
at 37° C. The migrated cells on the underside of the upper 
chamber were stained with phalloidin (P1951; Sigma-
Aldrich, St. Louis, Missouri, USA) and counted per 10 
high-power fields (×200) using a fluorescence microscope 
(FV1000; Olympus, Tokyo, Japan). These experiments 
were performed at least three times in each cell line.
Figure 6: Knockdown of ALCAM decreases the Wnt5a-induced increase in migratory capacity. (A) Wnt5a and ALCAM 
expression of MDA-MB-175-VII cells transfected with ALCAM-siRNAs (ALCAM-siRNA #1 and #2) and sc. (B) The migratory capacity 
of MDA-MB-175-VII cells transfected with ALCAM-siRNAs and sc. Data are presented as the mean ± SE of three migration assays. Data 
were evaluated using the Mann–Whitney U-test.
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Cell proliferation assay
The control MCF-7 and MCF-7/Wnt5a cells were 
seeded at densities of 1 × 105/mL as previously described 
[8]. Cells were enumerated on the incubated days.
Gene microarray analysis
For the Oligo DNA microarray analysis, cells were 
washed with phosphate-buffered saline once and collected 
with Buffer RLT (Qiagen, Hilden, North Rhine-Westphalia, 
Germany). Total RNA was extracted from cells using the 
RNeasy mini kit (Qiagen). The 3D-Gene Human Oligo 
chip 25 k (Toray Industries, Tokyo, Japan) was used. For 
efficient hybridization, this microarray has 3-dimensions 
constructed with a well as the space between the probes 
and cylinder-stems, with 70-mer oligonucleotide probes on 
the top. Total RNA was labeled with Cy5 using the Amino 
Allyl MessageAMP II aRNA Amplification Kit (Applied 
Biosystems, Foster City, California, USA). The Cy5-
labeled aRNA pools were placed in hybridization buffer 
and allowed to hybridize for 16 h using the supplier’s 
protocols (www.3d-gene.com). The hybridization 
signals were obtained using the 3D-Gene Scanner 
(Toray Industries) and processed by 3D-Gene Extraction 
(Toray Industries). Detected signals for each gene were 
normalized using the global normalization method, with 
the median of the detected signal intensity adjusted to 25.
Materials and chemicals
Anti-Wnt5a/b antibody was purchased from Cell 
Signaling Technology (Beverly, Massachusetts, USA). 
Anti-β-catenin and anti-ALCAM antibodies were 
purchased from BD Biosciences and Leica Biosystems, 
respectively. Anti-ER and anti-ErbB 2 antibodies were 
purchased from Abcam. Anti-β-actin and anti-cyclin D1 
antibodies were purchased from Sigma-Aldrich.
Statistical analysis
The correlation between immunohistochemical 
determination of Wnt5a expression and clinicopathologic 
factors in tumor tissues was analyzed using the Chi-
square test. The correlation between Wnt5a and ALCAM 
expression was analyzed by kappa coefficient. The Mann–
Whitney U-test was used to compare cell migration. 
P values < 0.05 were considered statistically significant. 
All calculations were performed using SPSS version 20.
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